Georgia Transvaginal Mesh Lawyer Speaks with Bloomberg News about Johnson & Johnson’s Failure to Stop Gynecare Prolift Sales

Share Article

Bloomberg News interviews Henry G. Garrard III of Georgia’s Blasingame, Burch, Garrard & Ashley, P.C., for an article on the sale of the Gynecare Prolift by Johnson & Johnson’s Ethicon unit after the FDA had ordered the manufacturer to stop marketing the vaginal mesh implants.

transvaginal mesh failure, transvaginal mesh problems, transvaginal mesh implants, vaginal mesh, pelvic mesh, surgical mesh, products, lawyer, attorney, lawsuit, law firm

Henry G. Garrard III

As we continue to work hard on developing these cases on behalf of our clients and prepare for trial, we’re encouraged to see the media focusing on these important woman’s health and medical device issues.

In a new article, Georgia transvaginal mesh attorney Henry G. Garrard III talks with Bloomberg News about the continued sale of Gynecare Prolift vaginal mesh implants by Johnson & Johnson’s Ethicon unit after the U.S. Food and Drug Administration (FDA) had ordered the company to halt sales in 2007.

According to the article, the FDA told Johnson & Johnson in writing in August 2007 to stop marketing the Gynecare Prolift until the agency determined whether the transvaginal mesh product was “substantially equivalent” to other products already on the market.

However, as it negotiated with the FDA during the next nine months, Johnson & Johnson did not stop selling the device, Bloomberg reports. The FDA cleared the device in May 2008.

In the article, Garrard tells Bloomberg News that the FDA’s failure to take further steps to stop Prolift sales while the pelvic mesh device was under review or to sanction the manufacturer for failing to stop sales raises questions about the agency’s power to protect patients.

“Companies know the FDA has little enforcement ability and scarce resources,” Garrard, the managing partner of the Athens, Georgia-based law firm of Blasingame, Burch, Garrard & Ashley, P.C., tells Bloomberg.

Garrard currently is serving as Coordinating Co-Lead Counsel for the Plaintiffs in the ongoing federal transvaginal mesh lawsuits in the U.S. District Court for the Southern District of West Virginia.

Garrard also serves as Co-Lead Counsel for the Plaintiffs in the pelvic repair mesh MDL against C.R. Bard, Inc. (MDL No. 2187), and he serves on the Executive Committee and the Plaintiffs’ Steering Committee. Firm partner Josh Wages also serves on the Plaintiffs’ Steering Committee.

The cases involve hundreds of women from across the U.S. who claim to have suffered physical and emotional injuries from defective vaginal mesh implants manufactured and sold by C.R. Bard, Inc., Johnson’s Ethicon unit (MDL No. 2327), American Medical Systems, Inc. (MDL No. 2325), and Boston Scientific Corp. (MDL No. 2326).

Garrard and his firm represent the plaintiffs who have been selected as potential bellwether plaintiffs for trial in the Bard MDL, and the firm is actively preparing for the first trial scheduled for early next year. The first bellwether trial in the Bard litigation has been set for the first week of February 2013.

“As we continue to work hard on developing these cases on behalf of our clients and prepare for trial, we’re encouraged to see the media focusing on these important woman’s health and medical device issues,” Garrard said.

“It’s important for the public to have as much information as it can about the health risks posed by certain vaginal mesh implants as well as to know more about how these products can get into the market in the first place.”

Garrard, who has been at the forefront of defective transvaginal mesh litigation since 2006, often is called upon by the media to discuss legal issues involving vaginal mesh implants as well as to comment on the FDA’s regulation of pelvic mesh and other medical devices.

Bloomberg News also interviewed Garrard in March for an article discussing Johnson & Johnson’s Gynecare Prolift vaginal mesh implants. In June, Johnson & Johnson announced that it would “stop commercializing” the Prolift as well as three other vaginal mesh implant systems – the Gynecare TVT Secur, Prosima and Prolift+M.

Over the years that he and his firm have been handling these cases, Garrard has been interviewed by several other media outlets about pelvic mesh devices and the firm’s work in this litigation, including Wall Street Journal, Chicago Tribune, Boston Globe, Florida Today, Fulton County Daily Report, South Florida Sun-Sentinel,, Lawyers USA and various television stations.

About Blasingame, Burch, Garrard & Ashley, P.C.
Blasingame, Burch, Garrard & Ashley, P.C., is an Athens, Georgia-based law firm that has been widely recognized for its ethics, skill and professionalism by Martindale-Hubbell®, The Best Lawyers in America, American College of Trial Lawyers, Super Lawyers and Law & Politics Media/Atlanta Magazine. Since 2006, the firm’s defective medical device and product liability lawyers have pursued claims involving defective transvaginal mesh products, including handling attorney referrals from co-counsel across the country. For more information, call the firm at (866) 354-3544 or use its online contact form.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Josh B. Wages

Mike Dayton
Visit website